Quick Answer
CASI Pharmaceuticals, Inc. reported Long Term Debt of $18.90 million for the year ending 2023.
- This data is from CASI Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2023 to 2023 (1 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: